Evaluation of the level of Antistreptolysin O Antibody in patients with acute myocardial infarction 6 months to 1 year secondary to streptokynase injection

  • سال انتشار: 1397
  • محل انتشار: نوزدهمین کنگره پژوهشی سالانه دانشجویان علوم پزشکی کشور
  • کد COI اختصاصی: AMSMED19_091
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 503
دانلود فایل این مقاله

نویسندگان

F Kazemi

Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

SH Sezavar

Rasool Akram Hospital of Iran University of Medical Sciences Tehran Iran

M Dehghani

Rasool Akram Hospital of Iran University of Medical Sciences Tehran Iran

چکیده

Background and objective:Injection of streptokinase leads to return of circulation in artery in 60% of cases of acute myocardial infarction(AMI). Because of presence of anti-streptolysin O Antibody (ASO), which leads to a reduction in streptokinase efficiency, the safe minimal duration of re-prescribing the drug should be further investigated. Controversy in determining safe minimum-time for re-prescription of streptokinase in different studies is seen. In this study we evaluated the ASO levels in AMI patients 6 months to 1 year after the initial injection in comparison with control group to determine the suitable time gap. Methods and Materials:In this analytical retrospective case-control study a number of 73 patients that had AMI in the past 6 months to 1 year who were treated with streptokinase in Rasul Akram, Firuzgar ,Firuz abadi hospital in 2013-2014 were recruited by non-probable convenience sampling. Patients’ diabetes history, hypertension history, hyperlipidemia, smoking history, and ASO level data was collected from their medical records & the detained blood sample. Patients who had a history of using streptokinase were excluded. The levels of Ab were compared and analyzed using independent sampling t-test and chi-square using SPSS v.24. Findings:A total number of 62 females (41.8%) including 21 AMI patients (33.8%) and 86 males (58.1%) including 52 AMI patients (60.4%) with mean± SD age of 56.79±9.98 in case group and 59.88±11 in control group were studied. Results showed no significant difference between case & control Group in ASO levels P=0.071. Results showed no significant difference between case & control Group regarding mellitus diabetes (17.8% in case group, 25.3% in control group), hypertension(41%in case group, 28% in control group) and pharyngitis(24.6% in case group, 30.6% in control group) P> 0.05. Hyperlipidemia (49% in case group,26.6% in control group) & renal dysfunction had a significantly higher rate in case group p=0.004. There was a significantly higher rate of smoking in case group (44%in case group,14.6% in control group) P< 0.001. The result showed no significant difference in ASO level between two groups separated into age groups. There was a significant difference in ASO levels in males and females separately between case and control groups P< 0.001. There was a significant difference in ASO levels between males and females in each case and control group (case: male> female, control: female> male) P< 0.05.Conclusion: Since no significant difference in ASO levels was observed and ASO is a substitute for streptokinase, according to this study it seems that in case of reoccurrence of AMI 6 months to 1 year after the initial prescription, streptokinase can be prescribed again.

کلیدواژه ها

Myocardial infarction (AMI), Antistreptolysin O (ASO), Streptokinase

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.